Core Viewpoint - Madrigal Pharmaceuticals has successfully launched Rezdiffra, the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieving significant patient engagement and positive feedback from healthcare providers [2][4]. Financial Results - First-quarter 2025 net sales for Rezdiffra reached $137.3 million, with over 17,000 patients treated as of March 31, 2025 [4][21]. - Operating expenses for the first quarter of 2025 were $216.6 million, compared to $152.0 million in the same period last year [21]. - Research and development expenses decreased to $44.2 million from $71.2 million year-over-year, primarily due to changes in accounting for inventory costs and reduced clinical trial expenses [21]. - Selling, general and administrative expenses increased to $167.9 million from $80.8 million, driven by commercial launch activities for Rezdiffra [21]. - The company reported a net loss of $73.2 million for the first quarter of 2025, compared to a net loss of $147.5 million in the prior year [21]. Corporate Updates - Madrigal appointed David Soergel, M.D., as Chief Medical Officer and Rebecca Taub, M.D., as Senior Scientific and Medical Advisor [4][9]. - The company has a strong presence at the upcoming EASL Congress, with six abstracts accepted, including late-breaking data from the MAESTRO-NAFLD-1 trial [5][4]. - Madrigal's cash, cash equivalents, restricted cash, and marketable securities totaled $848.1 million as of March 31, 2025, down from $931.3 million at the end of 2024 [21][23]. Product and Market Insights - Rezdiffra is designed to treat adults with MASH with moderate to advanced liver scarring and is the first medication approved for this indication [12][17]. - The company aims to reach approximately 315,000 patients with moderate to advanced fibrosis under the care of liver specialists in the U.S. [11]. - The MAESTRO-NAFLD-1 trial data indicates a mean reduction of 6.7 kPa in liver stiffness, with 51% of patients achieving a ≥ 25% reduction, which is associated with reduced progression to end-stage liver disease [5][4].

Core Insights - Madrigal Pharmaceuticals is set to present significant data on resmetirom at the EASL Congress, highlighting its potential to improve liver health in patients with compensated MASH cirrhosis [1][3] - The company is preparing for a European Commission decision regarding the marketing authorization application for resmetirom, with expectations to launch in Germany in the second half of 2025 [2] Company Overview - Madrigal Pharmaceuticals focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need [14] - Resmetirom is the first approved medication for MASH in the U.S., targeting key underlying causes of the disease [1][14] Clinical Data and Presentations - The late-breaking oral presentation at EASL will detail two-year data from the Phase 3 MAESTRO-NAFLD-1 trial, showing improvements in liver stiffness and fibrosis biomarkers in 122 patients [1][3] - Additional posters will cover various aspects of MASH, including baseline characteristics and the use of noninvasive tests for diagnosis [3] Market Context - An estimated 1.5 million patients in the U.S. have been diagnosed with MASH, with a focus on reaching approximately 315,000 patients with moderate to advanced fibrosis [7] - MASH is projected to become the leading cause of liver transplantation in the U.S., emphasizing the urgency for effective treatments [5][6]

Core Viewpoint - Madrigal Pharmaceuticals is set to release its first-quarter 2025 financial results on May 1, 2025, before the U.S. markets open [1] Company Overview - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - The company's primary medication, Rezdiffra (resmetirom), is a once-daily oral THR-β agonist targeting the underlying causes of MASH and is the first FDA-approved treatment for MASH with moderate to advanced fibrosis (F2 to F3 stages) [3] - An ongoing Phase 3 trial is assessing Rezdiffra for treating compensated MASH cirrhosis (F4c stage) [3] Upcoming Events - Following the financial results announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to discuss the financial and operational results [2] - The webcast will be accessible via the Investor Relations section of the Madrigal Pharmaceuticals website, with a recommendation for participants to register at least 15 minutes in advance [2]

CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to the role of Senior Scientific and Medical Advisor. Dr. Taub will continue to serve on Madrigal's Board of Directors. Succeeding ...

Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) [5] - The company's medication, Rezdiffra (resmetirom), is the first and only FDA-approved treatment for MASH with moderate to advanced fibrosis [6] Leadership Transition - Rebecca Taub, M.D., the founder and Chief Medical Officer, will transition to Senior Scientific and Medical Advisor while continuing on the Board of Directors [1] - David Soergel, M.D., has been appointed as the new Executive Vice President and Chief Medical Officer, effective April 21, 2025 [1] Achievements and Future Plans - Under Dr. Taub's leadership, Madrigal achieved the milestone of developing Rezdiffra, the first FDA-approved medicine for MASH, providing hope to patients [2][3] - Dr. Soergel brings over 20 years of experience in drug development for metabolic and cardiovascular diseases, which aligns with the company's goal to expand its pipeline beyond Rezdiffra [3][4] Company Growth - Madrigal has grown from a small team of fewer than 10 R&D professionals to a commercial-stage biopharma company with over 500 employees across the U.S. and Europe [3]

It has been about a month since the last earnings report for Madrigal (MDGL) . Shares have added about 0.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Madrigal due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns o ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, s ...

Madrigal Pharmaceuticals (MDGL) reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus Estimate of a loss of $4.12. In the year-ago quarter, the company had incurred a loss of $5.68 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.During the quarter, the company generated total revenues of $103.3 million entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), which was approved la ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL ) announced its Q4 and full-year 2024 earnings earlier today, and the market's initial response has been positive, with shares ...

Core Viewpoint - Madrigal Pharmaceuticals experienced a significant stock increase of 15.2% following the announcement of its fourth-quarter and full-year 2024 results, which exceeded market expectations [1]. Financial Performance - The company reported fourth-quarter revenue of $103.3 million, entirely from sales of its drug Rezdiffra, which is approved for treating metabolic dysfunction-associated steatohepatitis (MASH) [2]. - Madrigal posted a net loss of $59.4 million, equating to $2.71 per share, which was better than the consensus estimate of a net loss of $4.48 per share [2]. - The revenue performance surpassed Wall Street's average analyst estimate of $87.7 million for Q4 [2]. Investor Sentiment - Investors reacted positively to the revenue beat, as Madrigal had previously projected Q4 net sales of between $100 million and $103 million, thus exceeding the top end of this range [3]. - The company's CEO indicated strong future performance, stating that Madrigal is "well positioned for strong performance again in 2025 and beyond," which contributed to investor optimism [4]. Growth Potential - Analysts project that Rezdiffra could achieve peak annual sales close to $3.5 billion, suggesting significant growth potential for Madrigal Pharmaceuticals [5]. - With a market capitalization around $7.7 billion, there is perceived room for further stock price appreciation [5].